

PRIOR AUTHORIZATION REQUEST FORM NEUPRO® FOR RESTLESS LEGS

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Fai	lure to submit clinical documentati	on to support this request will	result i	n a disı	missal of the request.	
If y	ou have prior authorization question	ns, please call for assistance 385	5-425-5	094.		
Dis	claimer: Prior authorization request for	ms are subject to change in accord	dance w	th Fede	eral and State notice requirements.	
Date:		Member Name:		ID#:	ID#:	
DOB:		Gender:		Phys	Physician:	
Office Phone:		Office Fax:		Offic	Office Contact:	
Hei	ght/Weight:					
rea	offerred products has not been successful son for failure. Reasons for failure multiple for failure for	st meet the Health Plan medical n	-		· •	
	If the request is	for reauthorization, proceed to	o reaut	horizat	tion section	
Questions			Yes	No	Comments/Notes	
1.	Is this request for an expedited rev By checking the "Yes" box to reque hours), you are certifying that appl frame (72 hours) may place the me to regain maximum function in ser	est an expedited review (24 ying the standard review time ember's life, health, or ability				
2	Is the request for moderate-to-sev			П		
3.	If serum ferritin levels are ≤75 mcg	/L, has the member had a 3-			Please provide documentation	
4.	Has the patient tried and failed all pramipexole, pregabalin?				Please provide documentation	
5.	Is the patient unable to take medic therapy clinically inappropriate?				Please provide documentation	
		REAUTHORIZATION				
1.	Is the request for reauthorization of	f therapy?				
2.	Do updated progress notes show cand clinical efficacy?	, 			Please provide documentation	
	nat medications and/or treatment r me of treatment, reason for failure,		ne past	for this	s condition? Please document	

Additional information:	
Physician's Signature:	

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy PHARM-047

Origination Date: 04/06/2018 Reviewed/Revised Date: 05/17/2023 Next Review Date: 05/17/2024 Current Effective Date: 06/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.